Digital healthcare for respiratory disease

呼吸系统疾病的数字健康服务

Tony Kea)ng

Chief Execu)ve Officer and Managing Director tony@resapphealth.com.au

ASX Spotlight Investor Conference

30 May 2017, Singapore - 1 June 2017, Hong Kong

ASX: RAP

Disclaimer

This presenta)on has been prepared by ResApp Health Limited ("ResApp"). The informa)on contained in this presenta)on is a professional opinion only and is given in good faith. Certain informa)on in this document has been derived from third par)es and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjec)ve judgment and analysis and are subject to uncertain)es, risks and con)ngencies, many of which are outside the control of, and may be unknown to, ResApp. In par)cular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, compe))ve and economic uncertain)es and risks. Actual future events may vary materially from the forward-looking statements and the assump)ons on which the forward-looking statements are based. Recipients of this document (Recipients) are cau)oned to not place undue reliance on such forward-looking statements. ResApp makes no representa)on or warranty as to the accuracy, reliability or completeness of informa)on in this document and does not take responsibility for upda)ng any informa)on or correc)ng any error or omission which may become apparent aer this document has been issued.

To the extent permi]ed by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequen)al (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connec)on with, any use or reliance on this presenta)on or informa)on.

This presenta)on is not an offer, invita)on, solicita)on or recommenda)on with respect to the subscrip)on for, purchase or sale of any security, and neither this presenta)on nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

2

Digital healthcare for respiratory disease

  • Developing the world's first clinically-tested, regulatory-cleared respiratory disease diagnos)c test and management tools for smartphones

    开发世界首个经临床测试的监管无障碍的智能手机呼吸疾病诊断和管理工具

    • No addi'onal hardware needed 无需加装额外硬件
  • Huge global market, 700M+ doctor visits annually for respiratory disease1

    • Unique opportunity to integrate into telehealth providers' exis)ng placorms

    • Strong demand also seen within clinics, emergency rooms and outpa)ent facili)es

  • Compelling clinical evidence with 2,600+ pa)ents enrolled in pediatric and adult studies

  • Pediatric US FDA registra)on study underway at top-)er US hospitals

    • Target recruitment numbers for all disease endpoints have been reached
    • Top-line results expected in July 2017
  • FDA de novo submission planned for 3Q2017

  1. ResApp es)mate based on OECD doctor visits per capita data and assuming 10% of visits are for

respiratory disease (based on US data) 3

Company overview

Capital Structure (ASX:RAP)

Market Cap.

$231M

Share Price

as of 26 May 2017

$0.35

Shares on Issue1

659M

Performance Shares2

93.75M

Op)ons3

6.37M

Incen)ve Op)ons4

46.35M

Cash Balance

as of 31 March 2017

$10.3M

  1. Includes 62.4M escrowed shares (un)l 14/7/17)

  2. Issued on achieving AU$20M of annual revenue or on an acquisi)on

  3. 4.5M, exercise price of 28c, expire 29/4/19; 1.87M, exercise price of 30c, expire 29/4/19

  4. Issued to directors, staff and scien)fic advisory board

Board of Directors

Dr Roger Aston Non-Execu)ve Chairman

(Chairman of Oncosil Medical Ltd, formerly CEO of Mayne Pharma, Cambridge An)body, co-founder of pSivida Corp.)

Dr Tony Kea)ng Managing Director and CEO

(formerly Director, Commercial Engagement at UniQuest, engineering management roles with Exa Corpora)on)

Mr Brian Leedman Execu)ve Director and VP

(Non-Exec. Director of Alcidion Ltd, co-founder of Imugene Ltd and Oncosil Medical Ltd and formerly VP, IR at pSivida Corp, former Chair of AusBiotech-WA)

Mr Chris Ntoumenopoulos Non-Execu)ve Director

(Managing Director at Twenty 1 Corporate, Non-Execu)ve Director at Race Oncology, formerly at Ci)group, Indian Ocean Capital and CPS Capital)

Substan)al Shareholders

Fidelity Interna)onal: 8.22% Freeman Road: 6.84%

4

ResApp Health Limited published this content on 30 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 May 2017 00:01:13 UTC.

Original documenthttps://www.resapphealth.com.au/wp-content/uploads/2017/05/1678172.pdf

Public permalinkhttp://www.publicnow.com/view/BE7EF4EDF8C6F0B11749FA52666E52A756065296